Alliancebernstein L.P. Jounce Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.64 - $1.99 $4,096 - $12,736	6,400 Added 9.47%	74,000 $82,000
Q3 2022 Nov 15, 2022	BUY	$2.73 - $4.92 $6,825 - $12,300	2,500 Added 3.84%	67,600 $158,000
Q2 2022 Aug 15, 2022	BUY	$2.8 - $7.67 $8,400 - $23,010	3,000 Added 4.83%	65,100 $197,000
Q1 2022 May 13, 2022	BUY	$6.01 - $8.54 $1,202 - $1,707	200 Added 0.32%	62,100 $422,000
Q2 2021 Jul 30, 2021	BUY	$6.58 - $10.66 $39,480 - $63,960	6,000 Added 10.73%	61,900 $421,000
Q3 2020 Nov 12, 2020	SELL	$4.58 - $10.95 $2,748 - $6,570	-600 Reduced 1.06%	55,900 $456,000
Q2 2020 Aug 13, 2020	BUY	$4.17 - $7.58 $26,271 - $47,754	6,300 Added 12.55%	56,500 $390,000
Q1 2020 May 14, 2020	BUY	$2.91 - $8.7 $23,571 - $70,470	8,100 Added 19.24%	50,200 $238,000
Q2 2019 Aug 14, 2019	BUY	$4.3 - $6.73 $3,440 - $5,384	800 Added 1.94%	42,100 $208,000
Q3 2018 Nov 08, 2018	BUY	$6.5 - $8.37 $10,400 - $13,391	1,600 Added 4.03%	41,300 $268,000
Q2 2018 Aug 13, 2018	BUY	$7.27 - $21.88 $159,213 - $479,172	21,900 Added 123.03%	39,700 $304,000
Q1 2018 May 14, 2018	BUY	$13.4 - $28.4 $56,280 - $119,280	4,200 Added 30.88%	17,800 $398,000
Q4 2017 Feb 13, 2018	BUY	$12.52 - $17.82 $12,520 - $17,820	1,000 Added 7.94%	13,600 $173,000
Q3 2017 Nov 13, 2017	BUY	$11.17 - $16.99 $140,742 - $214,073	12,600	12,600 $196,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.